TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24467987
Drug: Stool substitute
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stool substitute preparation made from purified intestinal bacterial cultures derived from a single healthy donor
Study: 24467987
Drug: Stool substitute
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stool substitute preparation
Study: 24470004
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of 90-minute twice per week hatha yoga classes
Study: 24473178
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy with assessment of collateral grade
Study: 24473178
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy with robust angiographic collateral grade
Study: 24473509
Drug: Pharmacoinvasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacoinvasive treatment (tenecteplase thrombolysis followed by percutaneous coronary intervention)
Study: 24474568
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/day) with non-ritonavir HAART
Study: 24474568
Drug: Sunitinib (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (dose escalation from 25 mg/day to 50 mg/day) with ritonavir-based HAART
Study: 24475922
Drug: Empagliflozin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (25 mg once daily for 8 weeks)
Study: 24476740
Drug: Progenitor cell
Normalized name: Human glial progenitor cells
DrugBank: Human glial progenitor cells (DB18265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progenitor cell therapy (CD34+ selected cell suspension injected into the wound)
Study: 24476740
Drug: Sham side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham side (no progenitor cell treatment)
Study: 24476740
Drug: Histologic analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histologic analysis after progenitor cell treatment
Study: 24477328
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin (500 mg, once daily for 2-5 days) followed by oral azithromycin (500 mg, once daily for 7-10 days)
Study: 24477453
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate therapy (3-h intravenous infusion aiming to increase systemic lactate to ca. 5 mmol/L)
Study: 24477453
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate therapy
Study: 24477603
Drug: 15.5 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15.5 mg/m2 ombrabulin
Study: 24477603
Drug: 25 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m2 ombrabulin
Study: 24477603
Drug: 35 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg/m2 ombrabulin
Study: 24477603
Drug: 50 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m2 ombrabulin
Study: 24477837
Drug: Pill Placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill Placebo
Study: 24477837
Drug: Acute Treatment
Normalized name: Acute phase reactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute Treatment Responders
Study: 24477837
Drug: Acute Treatment
Normalized name: Acute phase reactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute Treatment Non-Responders
Study: 24480627
Drug: 25-hydroxyvitamin D
Normalized name: 25-hydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxyvitamin D <20 ng/ml
Study: 24480627
Drug: parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: parathyroid hormone ≥65 pg/ml
Study: 24480627
Drug: 25-hydroxyvitamin D
Normalized name: 25-hydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxyvitamin D ≥30 ng/ml
Study: 24480627
Drug: parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: parathyroid hormone <33 pg/ml
Study: 24480824
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m² intravenously, one or two doses)
Study: 24481953
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (TT) of vitamin K antagonist (VKA), aspirin, and clopidogrel
Study: 24482099
Drug: Subcutaneous pasireotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous pasireotide 600 μg bid for 15 days
Study: 24484064
Drug: Renal colic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal colic protocol CT with a mean dose-length product (DLP) of 746 mGy ⋅ cm (effective dose, 11.2 mSv)
Study: 24484064
Drug: Renal colic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal colic protocol CT with reduced dose (DLP of 200 mGy ⋅ cm or lower)
Study: 24487484
Drug: Adalimumab 24
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab 24 mg/m² (maximum 20 mg/dose) every other week up to 120 weeks
Study: 24488560
Drug: Rabbit anti-thymocyte
Normalized name: Rabbit anti-thymocyte immunoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit anti-thymocyte globulin (2.5 mg/kg/day for 4 doses)
Study: 24488798
Drug: Midostaurin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin (25 or 50 mg orally twice daily) + all-trans retinoic acid (ATRA) + CLAG chemotherapy
Study: 24490070
Drug: Second Generation
Normalized name: Second generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second Generation Antipsychotics
Study: 24491372
Drug: Daily self-monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-monitoring of peak cough expiratory flow, oxygen saturation, and respiratory discomfort
Study: 24492296
Drug: ARGX-110 (defucosylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARGX-110 (defucosylated IgG1 monoclonal antibody)
Study: 24493157
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg/day p.o.
Study: 24493215
Drug: LCP-Tacro once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCP-Tacro once-daily
Study: 24493287
Drug: Genetic targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic targeting of Cxcr2 receptor in murine model
Study: 24493717
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg twice per day for 1 month (cohort A)
Study: 24493717
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg twice per day for an average of 2.3 months (cohort B)
Study: 24496920
Drug: nab-paclitaxel 60
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 60 mg/m(2) weekly + cetuximab 250 mg/m(2) weekly + IMRT (70 Gy)
Study: 24496920
Drug: nab-paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 80 mg/m(2) weekly + cetuximab + IMRT
Study: 24496920
Drug: nab-paclitaxel 60
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 60 mg/m(2) weekly + cetuximab + IMRT
Study: 24497495
Drug: Antinuclear antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antinuclear antibodies (ANAs) positivity
Study: 24497495
Drug: Anticardiolipin antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticardiolipin antibodies (aCL) positivity
Study: 24500145
Drug: Elevated intact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated intact parathyroid hormone (PTH) (>62 pg/mL) with very low calcium intake (<60% of EAR) or insufficient 25-hydroxyvitamin D (<20 ng/mL)
Study: 24500145
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low 25(OH)D (<12 ng/mL)
Study: 24500145
Drug: Elevated PTH
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elevated PTH (>62 pg/mL)
Study: 24500148
Drug: Cobalt supplement
Normalized name: Cobalt supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobalt supplement (1.0 mg Co/d) for 90 days
Study: 24500152
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS) containing sodium selenite and antiretroviral drugs (ARV)
Study: 24500155
Drug: Magnesium intake
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium intake >422.5 mg Mg/d
Study: 24500940
Drug: 2 stable
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 stable magnesium isotopes (∼23 mg of oral ²⁶Mg and ∼11 mg of i.v. ²⁵Mg) administered to cohort 1
Study: 24501009
Drug: Dacomitinib (PF-00299804)
Normalized name: dacomitinib
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dacomitinib (PF-00299804) 45 mg once daily continuously in 21-day cycles
Study: 27280802
Drug: Multilayer Flow
Normalized name: zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multilayer Flow Modulator (MFM)
Study: 24502534
Drug: Intraarticular Botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular Botulinum toxin type A (BoNT-A) injection (100 units)
Study: 24502534
Drug: Intraarticular hyaluronate
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular hyaluronate injection plus rehabilitation exercise (30 minutes/day, 3 times/week for 4 weeks)
Study: 24502534
Drug: Intraarticular hyaluronate
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular hyaluronate injection plus rehabilitation exercise
Study: 24502534
Drug: Intraarticular BoNT-A
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular BoNT-A injection
Study: 24502608
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) optimization with echocardiography as reference
Study: 24503265
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human recombinant interferon-beta-1a (FP-1201) at an optimal tolerated dose of 10 μg per day for 6 days
Study: 24503265
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human recombinant interferon-beta-1a (FP-1201)
Study: 24504509
Drug: Vaccine-induced IgG
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-induced IgG antibodies to V1V2 regions of HIV-1 subtypes A, B, C, D, or CRF01_AE.
Study: 24504737
Drug: Lipopolysaccharide (low-dose)
Normalized name: sulfated mucopolysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipopolysaccharide (low-dose)
Study: 24506412
Drug: Montelukast monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast monotherapy (10 mg, once daily) in leukotriene-sensitive group
Study: 24506412
Drug: Montelukast monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast monotherapy (10 mg, once daily) in leukotriene-insensitive group
Study: 24508104
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy based on genomic alterations identified through CGH array and Sanger sequencing.
Study: 24508104
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy received by 43 assessable patients.
Study: 24508570
Drug: Permacol™ surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permacol™ surgical implant
Study: 24512954
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m² on days 1, 4, 8, and 11 of a 21-day cycle
Study: 24516013
Drug: R (rituximab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R (rituximab) 375 mg/m(2) once per week for 4 weeks
Study: 24516013
Drug: R +
Normalized name: Immune 24 Hour +
Approvals — FDA: no, EMA: no, PMDA: no
Description: R + MR (rituximab plus maintenance rituximab) administered once every 6 months for 2 years
Study: 24516026
Drug: Intravenous pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pegaspargase at 2,000 IU/m(2) per dose, administered in six doses with intervals longer than 4 weeks
Study: 24516026
Drug: Intravenous pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pegaspargase
Study: 24517219
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin G (IVIG) therapy (0.4 g kg(-1) day(-1) for 5 days)
Study: 24517417
Drug: 300IR birch
Normalized name: BIRCH TRITERPENES
DrugBank: Birch bark extract (DB16536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300IR birch pollen sublingual solution
Study: 24519196
Drug: Transdermal nanostructured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nanostructured formulation of progesterone (10%) combined with estriol (0.1%) + estradiol (0.25%)
Study: 24519196
Drug: Transdermal nanostructured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nanostructured formulation of progesterone and estrogens
Study: 24520093
Drug: MAGE-A3 peptide
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE-A3 peptide vaccine combined with Poly-ICLC (Hiltonol), granulocyte macrophage colony-stimulating factor (GM-CSF) ± montanide
Study: 24520094
Drug: Vaccine containing
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine containing GD2 and GD3 (30 μg each) and OPT-821 (150 μg/m²) with β-glucan (40 mg/kg/day, 14 days on/14 days off)
Study: 24522441
Drug: >35% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: >35% of daily energy intake from fat
Study: 24522441
Drug: Daily fiber
Normalized name: Daily Fiber Sugar-Free
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily fiber intake
Study: 24523241
Drug: Plerixafor (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (0.01 to 0.02 mg/kg, subcutaneously, twice daily for 6 months)
Study: 24523241
Drug: Plerixafor (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (0.01 to 0.02 mg/kg, subcutaneously, twice daily for 6 months) in combination with imiquimod
Study: 24524285
Drug: Weight-reduction program
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-reduction program including daily caloric restriction and exercise for 12 weeks
Study: 24525446
Drug: Theophylline/corticosteroid combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline/corticosteroid combination therapy
Study: 24526575
Drug: Bortezomib plus
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib plus irinotecan (1.3 mg/m² days 1, 4, 8, 11; 125 mg/m² days 1, 8 every 21 days)
Study: 24526575
Drug: Bortezomib alone
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib alone (as second line therapy)
Study: 24527713
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with 25OHD status of 20 ng/mL or greater
Study: 24527713
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with plasma 25OHD less than 20 nmol/L
Study: 24527713
Drug: Overweight/obese subjects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overweight/obese subjects with 25OHD status of 20 ng/mL or greater
Study: 24527713
Drug: Normal weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal weight subjects with 25OHD status of 20 ng/mL or greater
Study: 24528505
Drug: Home Dialysis
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home Dialysis Virtual Ward (HDVW) intervention with weekly clinician-led telephone interviews for 2 weeks until VW discharge.
Study: 24529163
Drug: Infliximab 3
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 3 mg/kg plus methotrexate (MTX) for 14 weeks
Study: 24529291
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (ramipril), specific dosage and duration not mentioned.
Study: 24530971
Drug: Fludarabine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (up to 210 mg/m2)
Study: 24531544
Drug: Metformin treatment;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment; specific dosage and duration not mentioned.
Study: 24531544
Drug: AMPK activators
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMPK activators (including metformin); specific dosage and duration not mentioned.
Study: 24534108
Drug: 5-azacitidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-azacitidine (75 mg/m² for 5 to 7 days every 4 weeks until a suitable donor was found)
Study: 24534286
Drug: Low age
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low age of menarche, high levels of high-sensitivity C-reactive protein and liver enzymes, low levels of sex hormone-binding globulin
Study: 24554062
Drug: Neoadjuvant sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant sorafenib (dose escalation cohort 1: 200 mg twice daily, cohort 2: 200/400 mg daily) plus preoperative conformal radiotherapy (50 Gy in 25 fractions)
Study: 24557359
Drug: Midstromal implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midstromal implant of an isolated Bowman layer graft
Study: 24558033
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose naltrexone (4.5 mg/day) for 12 weeks in adults
Study: 24558033
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose naltrexone (0.1 mg/kg, maximum 4.5 mg/day) for 8 weeks in children
Study: 24558033
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose naltrexone and placebo
Study: 24559321
Drug: Intravenous anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous anidulafungin followed by oral azole therapy (fluconazole or voriconazole) after 5 days if criteria met
Study: 24559321
Drug: Early switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early switch to oral azole therapy (≤ 7 days' anidulafungin)
Study: 24559321
Drug: Intravenous anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous anidulafungin followed by oral azole therapy
Study: 24559465
Drug: Urinary [TIMP-2]·[IGFBP7]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary [TIMP-2]·[IGFBP7] greater than 0.3 (ng/ml)(2)/1,000
Study: 24561146
Drug: Recovery of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery of normal LV function and size after treatment
Study: 24562448
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy with docetaxel (40 mg/m²), cisplatin (40 mg/m²), and panitumumab (6 mg/kg) with radiation therapy (5040 cGy, 180 cGy/day × 28 days) starting week 5.
Study: 24562641
Drug: FDG PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG PET/CT during radiotherapy (mean dose 43 Gy)
Study: 24563078
Drug: Continuous-infusion topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-infusion topotecan (0.4 mg/m² per day for 9-10 days every 3 weeks) with erlotinib (150 mg orally on days 1-10 of each cycle)
Study: 24563078
Drug: Continuous-infusion topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-infusion topotecan with erlotinib
Study: 24563480
Drug: PM01183 (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM01183 (4.0 mg/m(2) recommended dose)
Study: 24563480
Drug: PM01183 (7.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM01183 (7.0 mg flat dose)
Study: 24563480
Drug: PM01183 (recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM01183 (recommended dose)
Study: 24563480
Drug: PM01183 (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM01183 (at or above recommended dose)
Study: 24563781
Drug: Duloxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine treatment for 12 weeks
Study: 24564178
Drug: CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP levels in patients without diabetes mellitus who are not receiving statin therapy
Study: 24564281
Drug: MRI in
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI in CF patients with exacerbations before treatment
Study: 24564281
Drug: MRI in
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI in CF patients with exacerbations after antibiotic therapy
Study: 24565221
Drug: Saxagliptin 2.5
Normalized name: sAXagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 2.5 mg BID plus metformin
Study: 24566706
Drug: PF-03446962 10
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-03446962 10 mg/Kg intravenously fortnightly until disease progression or unacceptable toxicity